Table 1 Patient baseline characteristics
Parameter/statistic | Dose-escalation phase (n = 31) | Dose-expansion phase (n = 25) | Overall (n = 56) |
|---|---|---|---|
Age (years) | |||
Median (range) | 53 (38–70) | 56 (30–65) | 55 (30–70) |
Sex, n (%) | |||
Male | 23 (74.2) | 17 (68.0) | 40 (71.4) |
Female | 8 (25.8) | 8 (32.0) | 16 (28.6) |
ECOG PS, n (%) | |||
0 | 0 (0) | 0 (0) | 0 (0) |
1 | 31 (100) | 25 (100) | 56 (100) |
Primary site, n (%) | |||
Right-sided | 5 (16.1) | 2 (8.0) | 7 (12.5) |
Left-sided | 26 (83.2) | 23 (92.0) | 49 (87.5) |
Presence of liver metastases, n (%) | |||
Yes | 21 (67.7) | 22 (88.0) | 43 (76.8) |
No | 10 (32.3) | 3 (12.0) | 13 (23.2) |
Previous anticancer treatment, n (%) | |||
Surgery | 25 (80.6) | 22 (88.0) | 49 (87.5) |
Radiotherapy | 8 (25.8) | 11 (44.0) | 19 (33.9) |
Number of prior chemotherapy lines, n (%) | |||
1 | 1 (3.2) | 1 (4.0) | 2 (3.6) |
2 | 16 (51.6) | 9 (36.0) | 25 (44.6) |
≥ 3 | 14 (45.2) | 15 (60.0) | 29 (51.8) |
Prior treatment with bevacizumab, n (%) | 8 (25.8) | 6 (24.0) | 14 (25.0) |
Disease course (months) | |||
Median (range) | 21.3 (4.4–169.3) | 23 (6.2–88.0) | 22.2 (4.4–169.3) |